Condition: Arrhythmogenic Cardiomyopathy · Arrhythmogenic Right Ventricular Cardiomyopathy · Sponsor: Hamilton Health Sciences Corporation
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
This description comes directly from the study's public registry record.
Jason Roberts, MD MAS · 905-521-2100 · jason.roberts@phri.ca
Maha Mushtaha · maha.mushtaha@phri.ca
Always discuss trial participation with your own doctor first.
| University of Calgary | Calgary, Alberta, Canada | Recruiting |
| University of British Columbia | Vancouver, British Columbia, Canada | Recruiting |
| Victoria Cardiac Arrhythmia Trials Inc. | Victoria, British Columbia, Canada | Recruiting |
| NL Health Services | St. John's, Newfoundland and Labrador, Canada | Recruiting |
| Nova Scotia Health | Halifax, Nova Scotia, Canada | Recruiting |
| Hamilton General Hospital | Hamilton, Ontario, Canada | Recruiting |
| Kingston General Hospital | Kingston, Ontario, Canada | Not Yet Recruiting |
| London Health Sciences Centre | London, Ontario, Canada | Recruiting |
| Newmarket Electrophysiologist Research Group 'NERG' | Newmarket, Ontario, Canada | Not Yet Recruiting |
| University of Ottawa Heart Institute | Ottawa, Ontario, Canada | Not Yet Recruiting |
| Heart Health Institute Research Inc | Scarborough Village, Ontario, Canada | Recruiting |
| Sunnybrook Health Sciences Centre | Toronto, Ontario, Canada | Not Yet Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06174220